De-rating risk — paying ~27× trailing for ~7% organic growth leaves no margin if procedure volumes or price/tariff dynamics soften
One-line thesis. STERIS is a boring-in-a-good-way infection-prevention near-monopoly — FY26 revenue $5.94B (+9% reported / +7% organic), record adjusted EPS $10.17, FCF $983M, net-debt/EBITDA under 1× — but the stock is down ~10% over the past year and still trades at a full ~27× trailing GAAP earnings for only mid-single-digit organic growth, so it earns a Watch: own the quality, but not at any price and not while it's below its 200-day line.
◆ Synthos call — WatchSTE is a business we want at a price we don't have — it becomes a Buy below ~$207; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Low beta 0.92, net-debt/EBITDA 0.9× & non-cyclical demand — but ~27× trailing GAAP EPS on ~7% organic growth and a downtrend below the 200-DMA.
Growth Quality
6/10 · High
Steady mid-single-digit organic revenue, ~9-11% adj-EPS guide, expanding margins & recurring service mix — quality but not fast.
Exponential Potential
3/10 · Low
Mature ~$21B infection-prevention leader; growth decelerating, no acceleration or large untapped TAM — a compounder, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 16%/yrTo justify today’s $218, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
STERIS makes the products and services that keep hospitals and drug factories sterile — the machines and chemicals that clean and sterilize surgical instruments, and a big outsourced business that sterilizes medical devices for the companies that make them. Every surgery and every implanted device needs this, so demand is steady and repeats year after year. It is a very solid, unexciting business.
Is the stock cheap? Not really — it's fairly-to-fully priced. You pay about 27 dollars for every 1 dollar of last year's reported profit, which is a premium for a company growing sales only in the mid-single digits. And unlike most quality names right now, the stock has actually fallen about 10% over the past year while the market rose ~20%.
Our verdict is Watch: a great, dependable company, but the price and the falling chart don't give you a clear bargain today. It's one to keep on a list and buy on weakness or a fresh catalyst.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly safe). Barely any debt, a calm stock that doesn't swing much, and demand that doesn't disappear in a recession — but the full price and the downtrend are the catch.
Growth Quality 6/10 (good, not great). Reliable and profitable, with growing repeat-service revenue — but it grows slowly.
Exponential Potential 3/10 (low). This is a mature leader in a mature field. Expect steady singles, not a home run.
The one big worry: you're paying a premium price for slow, steady growth. If hospital procedure volumes soften, or tariffs and inflation keep eating margins, the stock could simply re-rate lower — which is arguably what the last year's decline has already begun to price in.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = STE · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$218.20
Market cap$21B
P/E trailing10×
P/E FY26E / FY27E21× / 20×
EV / Sales3.9×
EV / EBITDA12.5×
Gross margin44.2%
Net margin13.2%
Dividend yield1.15%
Beta0.923
52-wk range$199 – $269
RSI(14)63
50 / 200-DMA$212 / $237
12-mo return+-10% (SPY +21%)
Street target$270 ($269–$270)
Analyst grades11 Buy · 2 Hold · 0 Sell
FMP ratingA-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on STE · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
STERIS plc (NYSE: STE) is an Ireland-domiciled, Ohio-run global leader in infection prevention. Its fiscal year ends March 31 (FY26 = year ended 2026-03-31). The company runs three segments:
Healthcare (~72% of revenue) — sterilization and washing capital equipment, surgical consumables, endoscope reprocessing, and a large, sticky service and repair business for hospitals and surgical centers. Q4 FY26 Healthcare revenue $1.14B, +7%, with 9% service growth.
Life Sciences (~9%) — sterilizers, washers, cleanroom chemistries and consumables for pharma/biopharma manufacturing. Q4 revenue $163M, +9%.
Revenue mix (FY26, from FMP segmentation):
By type: Product $3.06B (52%) · Service $2.88B (48%). The near-half service mix is the quality tell — it's recurring, high-retention, and less cyclical than capital equipment.
By geography: United States $4.33B (73%) · other foreign $1.49B · Ireland $0.11B. US-concentrated, which ties demand to US hospital procedure volumes and exposes the P&L to US tariff/inflation dynamics (management explicitly cited tariffs pressuring Healthcare operating income in Q4).
This is a wide-moat, low-drama compounder: essential, recurring, non-discretionary demand, tied to the secular growth of surgical procedure volumes and the rising installed base of sterilized medical devices.
2. The expert thesis
There is no expert coverage of STE in the Synthos knowledge base.total_claims = 0; there are zero net-bullish (or bearish) voices and zero traceable claim_ids. Honesty is the product, so we state it plainly: nothing in this note rests on expert conviction. The verdict below is entirely fundamentals- and quant-driven — the reported financials, the analyst estimates and guidance (FMP + SEC 8-K), the valuation math, and the technical picture.
For context only (not Synthos conviction): the sell-side is constructive — 11 Buy, 2 Hold, 0 Sell, consensus rating "Buy," FMP letter rating A-, and a price-target consensus of $269.5 (a tight $269–$270 band from a thin set of targets). We treat that as the market's framing to react to, not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Moderate-Low
Beta 0.92, net-debt/EBITDA 0.9×, interest coverage 18×, non-cyclical recurring demand and ~half service revenue — genuinely defensive. Offsets: ~27× trailing GAAP EPS on ~7% organic growth, and the stock is below its 200-DMA in a 12-month downtrend.
Growth Quality
6 · Good
Steady ~7% constant-currency organic revenue, guided 9–11% adjusted-EPS growth, gross margin 44% and rising, ROIC ~8.5% (moat-worthy but not elite), durable service annuity. Quality — but slow, and capital-intensive (54% of assets are goodwill/intangibles from M&A).
Exponential Potential
3 · Low
A mature ~$21B category leader. Revenue growth is decelerating (FY26 +9% reported ≈ FY27 guide +7–8%), the TAM is large but already well-penetrated by STERIS, and the market cap leaves no room for a multibagger. Own it for singles.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Procedure volumes accelerate, AST capital equipment recovers, tariff/inflation drag eases; FY28E adj EPS beats to ~$12.75 (vs ~$12.19 cons); the market re-rates the defensive compounder back to ~22× forward adj EPS.
~$285 (+31%)
Base(our anchor)
Guidance roughly holds — FY27 adj EPS ~$11.20 (mid of $11.10–$11.30), FY28E ~$12.19; a steady 7% organic / ~10% adj-EPS compounder earns a ~20–21× forward adj-EPS multiple.
~$235 (+8%)
Bear
Procedure-volume softness or a hospital capex pause; tariffs/inflation compress Healthcare margin; FY27 adj EPS misses toward ~$10.60 and the multiple de-rates to ~16–17× as the downtrend persists.
~$175 (−20%)
Synthos fair value = the base case, ~$235 (+8%), with the full $175–$285 span as the honest range. Our base sits below the Street's $270 consensus — the sell-side is anchoring on ~24× forward adj EPS, which we think is rich for a mid-single-digit organic grower in a downtrend; we underwrite ~20–21× and get a more modest single-digit upside. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). STE is a solid compounder with essentially no exponential profile:
Forward growth: revenue CAGR FY26→FY29E ~6.5% ($5.94B → ~$7.18B, per FMP consensus); GAAP EPS CAGR ~18% ($7.93 → ~$13.20) — but note the EPS growth is flattered by amortization roll-off, buybacks (new $1B repurchase authorization) and margin, not by volume. On adjusted EPS the guide is a steadier ~9–11%/yr.
Acceleration (the 2nd derivative) is slightly negative: reported revenue growth is +9% FY26 → +7–8% guided FY27. There's no inflection here — it's a mature market growing with procedure volumes plus tuck-in M&A.
Room to run: the infection-prevention/contract-sterilization TAM is large, but STERIS is already the leader — this is share consolidation and end-market growth, not a greenfield land-grab. At ~$21B market cap the law of large numbers plus mid-single-digit organic growth caps any multibagger case.
Reinvestment runway: disciplined, modest — ~$375M/yr capex (incl. a new $60M Ohio sterility-assurance plant), FCF ~$850M guided FY27, returned via dividend + buyback. Healthy, but a return-of-capital profile, not a reinvest-for-hypergrowth one.
Exponential Potential: Low (3/10). Own STE for dependable high-single/low-double-digit total returns (organic growth + margin + buyback + ~1.2% dividend), not for a fast multibagger. That's not a knock on quality — it's an honest read of the math.
Margins: gross 44.2% TTM (rising from ~43% FY25), EBITDA margin 30.8%, operating ~18.6%, net 13.2%. Management flagged tariffs + inflation as the main offsets to price/volume gains in Healthcare — a margin watch-item.
Earnings: GAAP net income $785M FY26, EPS $7.93 (up from $6.24 FY25). Adjusted EPS $10.17 (+10% vs $9.22 FY25) — the number management and the Street anchor on; the GAAP/adjusted gap is mostly acquired-intangible amortization.
Balance sheet: total debt $2.09B, cash $440M, net debt $1.65B → net-debt/EBITDA 0.9× (down from ~2.0× in FY24 post-Cantel deleveraging). Investment-grade, interest coverage 18×, current ratio 2.1×. A genuinely strong balance sheet. Note: goodwill + intangibles are 54% of assets ($5.8B) — a legacy of the Cantel/US Endoscopy acquisitions; watch for impairment if returns disappoint.
6. Valuation — priced in or room?
STE is fairly-to-fully valued, not cheap. On trailing numbers it's 27.4× GAAP EPS, or ~21× adjusted EPS ($218.20 / $10.17). On the forward guide, ~19.5× FY27E adjusted EPS (mid-point $11.20) — a reasonable but not bargain multiple for a defensive mid-single-digit grower. EV/EBITDA 12.5× and EV/sales 3.9× are middling for med-tech quality. The PEG on adjusted EPS (~2×) says you're paying up relative to the growth rate.
The bull's defense is that the multiple compresses as adjusted EPS compounds ~10%/yr and the buyback shrinks the share count. The bear's rebuttal is that a ~7%-organic-growth business shouldn't command a growth multiple, and the market seems to agree — hence the ~10% 12-month decline while the S&P rose ~20%. Street targets (context): consensus $270, high $270, low $269 — a tight, constructive band implying ~24× forward adj EPS. We anchor lower (~20–21×) and get a ~$235 base case; the Street's optimism is the gap to watch. This is a quality-at-a-full-price name — worth owning on a pullback, not chasing here.
7. Technicals (from the tech block)
Trend: down. $218 sits just above the 50-DMA ($212) but below the 200-DMA ($237) — the 50 is below the 200 (death-cross posture). MACD only marginally positive (+0.28). This is a stock trying to base, not one in an uptrend.
Location:−19% off the 52-week high ($268.65), +9% off the 52-week low ($199.40). Max drawdown from peak −18.8% — a real correction, not a leadership breakout.
Momentum: RSI(14) 63 — firm but not overbought; consistent with the recent bounce off the lows toward the 50-DMA.
Relative strength (the tell): STE −10.1% 12-mo vs SPY +20.6% and QQQ +30.3%; −0.8% 3-mo vs SPY +13.7%. Persistent underperformance of both the market and growth — the opposite of a momentum name.
Read: technicals do not confirm a buy. The stock is below its 200-day line and has lagged badly for a year. A reclaim of the 200-DMA (~$237) on volume would be the technical green light; until then, the chart argues for patience — consistent with the Watch verdict.
8. Moat & competitive position
STERIS's moat is real and multi-layered: (1) scale and breadth — the broadest infection-prevention portfolio, spanning capital equipment, consumables and service across hospital and pharma; (2) switching costs and a service annuity — once STERIS equipment and reprocessing workflows are installed, the recurring service/consumable stream is sticky and high-margin (~half of revenue is service); (3) AST as a quasi-utility — contract sterilization is capacity-gated, regulation-heavy, and consolidated among few players (STERIS and Sotera/Nordion-type peers), giving pricing power; (4) regulatory/validation barriers — sterility assurance is mission-critical and validated, so customers don't switch casually. Returns on capital (ROIC ~8.5%, ROE 11%) are solid though not spectacular, weighted down by the acquisition-heavy asset base.
Peer set (FMP, market cap): the FMP peer list is a broad med-tech basket rather than pure sterilization comps — Waters $24.7B, West Pharmaceutical $25.8B, Zimmer Biomet $16.9B, Labcorp $23.5B, Quest Diagnostics $23.9B, DexCom $27.5B, Biogen $31.9B, Insulet $11.4B, Smith & Nephew $12.8B, Philips $26.9B. STE sits mid-pack on size; its closest economic analogues (contract sterilization, sterility assurance) aren't in this list. Versus the basket, STE offers lower growth but higher defensiveness than the diagnostics/device names.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly. FY26 returned ~$236M in buybacks and ~$242M in dividends; the Board authorized a new $1B repurchase program (May 2026). Capex is modest (~$375M guided FY27, including a $60M Ohio consolidation plant). Post-Cantel deleveraging took net-debt/EBITDA from ~2.0× to 0.9× — a clean, conservative sheet. Dividend $2.52/yr (~1.2% yield), payout ~31% — well-covered and growing.
Insider activity: the sampled window (June–July 2026) shows routine, non-alarming activity — mostly F-InKind tax-withholding dispositions on vesting and a director option exercise; one small officer sale (~$0.3M). No cluster of discretionary insider selling that would flag concern.
Management's own guidance — FY27 outlook (from the SEC 8-K earnings release, 2026-05-11 — self-interested words, half-weighted): management guides reported revenue +7–8% (constant-currency organic +6–7%), adjusted diluted EPS $11.10–$11.30 (+9–11% vs $10.17), at a ~25% tax rate; capex ~$375M and free cash flow ~$850M. This is a real earnings release (revenue, segment detail, explicit forward outlook), so we weight it as credible-but-management's-own-book. It reads as steady mid-single-digit organic growth converted into low-double-digit adjusted EPS via price, mix, margin and buyback — exactly the compounder profile our scores reflect. Note FY27 FCF guidance (~$850M) is below FY26's $983M, reflecting the new plant investment and working-capital normalization — a modest near-term FCF headwind to watch.
10. Catalysts & what to watch
Next earnings: 2026-08-05 (Q1'27; Street EPS $2.52, revenue ~$1.50B). The key lines: Healthcare organic growth and operating margin (tariff/inflation offset) and AST capital-equipment trend (the swing factor on organic growth).
Procedure volumes: US hospital surgical/procedure volumes are the demand driver — acceleration is the bull trigger, softness the bear trigger.
Margin vs tariffs/inflation: management flagged tariffs pressuring Healthcare operating income — watch whether price/productivity outpaces the drag.
Buyback execution: how aggressively the new $1B authorization is deployed at these levels supports EPS.
Technical: a reclaim of the 200-DMA (~$237) would flip the chart from "Watch" toward "add."
Thesis tripwires (what would change the call): two consecutive quarters of organic revenue below ~5%; adjusted-EPS guidance cut; a Healthcare margin break from tariffs/inflation; or a goodwill/intangible impairment. A pullback into the low-$190s (toward the 52-wk low) with intact fundamentals would, conversely, make the risk/reward clearly attractive.
11. Key risks
Valuation / de-rating (the main risk): ~27× trailing GAAP EPS for ~7% organic growth offers little margin; the 12-month downtrend suggests the market is already re-rating.
Tariffs & input inflation: explicitly cited by management as an offset to Healthcare operating income — a live margin threat given US manufacturing/import exposure.
Procedure-volume cyclicality: demand tracks US hospital surgical volumes; a slowdown (macro, staffing, or reimbursement-driven) hits the Healthcare segment.
AST capital-equipment lumpiness: the highest-margin segment's reported growth swings with capital-equipment timing (Q4 FY26 showed a 62% capital-equipment decline masked by service growth).
Acquisition-heavy balance sheet: goodwill + intangibles are 54% of assets (Cantel legacy) — impairment risk if returns disappoint; integration/M&A dependence for above-organic growth.
No expert coverage: with zero KB claims, there is no independent conviction cross-check — the call is model-only and should be sized accordingly.
12. Verdict, position sizing & monitoring
Watch. STERIS is a genuinely high-quality, wide-moat, low-beta infection-prevention leader with a fortress balance sheet (net-debt/EBITDA 0.9×), strong FCF ($972M), a growing dividend and a fresh $1B buyback — a textbook defensive compounder. But two things hold it back from a Buy today: (1) the valuation is full (~27× trailing GAAP / ~19.5× forward adjusted) for only mid-single-digit organic growth, and (2) the technicals are in a downtrend (below the 200-DMA, −10% over 12 months vs a +20% market). Our base-case fair value (~$235, +8%) sits below the Street's $270. With no expert coverage to add conviction, the honest call is to keep it on the list and buy on weakness or a fundamental re-acceleration, not to chase it here.
Sizing: if bought, a defensive-quality satellite, ~1–3% — and ideally scaled in on a pullback toward the low-$200s / high-$190s or a reclaim of the 200-DMA. Not a core conviction position given zero KB breadth.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $218.20.
Single biggest risk: de-rating — paying a premium multiple for slow growth, which the past year's decline has already begun to price in.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of STE in the Synthos knowledge base, and this note says so plainly. The verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here, no claim_ids exist to cite.
Data as-of: fundamentals 2026-03-31 (FY26, ended March 2026) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K dated 2026-05-11. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
Management caveat: FY27 guidance is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").